<%server.execute "isdev.asp"%> Levetiracetam as a first‑line agent for neonatal seizure Mandal A, Sahi PK - J Pediatr Neurosci
home : about us : ahead of print : current issue : archives search instructions : subscriptionLogin 
Users online: 768      Small font sizeDefault font sizeIncrease font size Print this page Email this page


 
  Table of Contents    
LETTER TO THE EDITOR
Year : 2017  |  Volume : 12  |  Issue : 4  |  Page : 395-396
 

Levetiracetam as a first‑line agent for neonatal seizure


1 Department of Pediatrics, Sitaram Bhartia Institute of Science and Research, New Delhi, India
2 Department of Pediatrics, Kalawati Saran Children’s Hospital, New Delhi, India

Date of Web Publication26-Mar-2018

Correspondence Address:
Dr. Anirban Mandal
B‑16 Qutub Institutional Area, New Delhi ‑ 110 016
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/JPN.JPN_61_17

Rights and Permissions

 



How to cite this article:
Mandal A, Sahi PK. Levetiracetam as a first‑line agent for neonatal seizure. J Pediatr Neurosci 2017;12:395-6

How to cite this URL:
Mandal A, Sahi PK. Levetiracetam as a first‑line agent for neonatal seizure. J Pediatr Neurosci [serial online] 2017 [cited 2020 Sep 18];12:395-6. Available from: http://www.pediatricneurosciences.com/text.asp?2017/12/4/395/227980


Dear Sir,

We read with much interest the article by Falsaperla et al., published in the recent issue of your journal,[1] but at the same time would like to make the following comments, clarification to which would benefit the general readers of JPN.

The abstract mentions the study period to be “from January to August 2016” but the materials and methods section state it to be “July 2015 to July 2016.” This makes the readers wonder about the actual period of the study.

The materials and methods section mentions that preterm and “on‑term” neonates “with signs and/ or symptoms of the convulsive disease and/or hypoxic‑ischemic disease” “who needed anticonvulsant therapy” were included. This makes one wonder whether neonates with hypoxic‑ischemic encephalopathy who did not have seizure and might have actually not required antiepileptic, were also included in the study. Again, the authors also mention that the neonates were “randomly included.” It is not clear whether they meant any form of “random sampling” such as “simple random sampling” or they had chosen the participants at their will/convenience or actually they are presenting selective data of neonates with seizure who received levetiracetam as the first‑line agent among all such neonates in their nursery! This leads to a serious concern of “selection bias” in the study.[2] As they also do not mention how the sample size was calculated,[3] this issue of presentation of “selective data” of patients is further suspected.

It is mentioned that “magnetic resonance imaging was performed in 40% of cases” but 40% of total cases (16) comes to be 6.4!

The text in results mention that “Electroencephalogram (EEG) study before treatment showed the presence of brushes in 12.5% of patients, diffuse cortical involvement in 12.5% of cases, and centrotemporal spikes in 12.5% of patients,” while [Figure 2] presents “Video EEG alterations of the studied patients before the onset of symptoms (?)” reveal tonic–clonic seizure in 50%, delta brushes in 12.5%, spikes in 25%, and cortical cerebral sufferance (?) in 12.5%! Again, the symptomatology [Figure 1] describes tonic–clonic convulsions in 12.5%. First, tonic–clonic seizure is a clinical diagnosis and not an EEG feature. Second, generalized tonic–clonic seizure being extremely rare in newborns, it is very surprising to have either 12.5% or 50% of newborns to have the same. On the other hand, subtle seizure, which is the most common type of seizure in this age group,[4] was not seen in cohort.
Figure 1: Symptoms for which levetiracetam was started in the studied population

Click here to view
Figure 2: Video electroencephalogram alterations of the studied patients before the onset of symptoms

Click here to view


Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
   References Top

1.
Falsaperla R, Vitaliti G, Mauceri L, Romano C, Pavone P, Motamed‑Gorji N, et al Levetiracetam in neonatal seizures as first‑line treatment: A prospective study. J Pediatr Neurosci 2017;12:24‑8.  Back to cited text no. 1
    
2.
Miller KD, Rahman ZU, Sledge GW Jr. Selection bias in clinical trials. Breast Dis 2001;14:31-40.  Back to cited text no. 2
    
3.
Malone HE, Nicholl H, Coyne I. Fundamentals of estimating sample size. Nurse Res 2016;23:21‑5.  Back to cited text no. 3
    
4.
Panayiotopoulos CP. Neonatal Seizures and Neonatal Syndromes. The Epilepsies: Seizures, Syndromes and Management. Ch. 5. Oxfordshire (UK): Bladon Medical Publishing; 2005. Available from: https://www.ncbi.nlm.nih.gov/books/NBK2599/. [Last accessed on 2017 May 05].  Back to cited text no. 4
    


    Figures

  [Figure 1], [Figure 2]



 

Top
Print this article  Email this article
 
 
  Search
 
  
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Article in PDF (566 KB)
    Citation Manager
    Access Statistics
    Reader Comments
    Email Alert *
    Add to My List *
* Registration required (free)  


    References
    Article Figures

 Article Access Statistics
    Viewed1179    
    Printed12    
    Emailed0    
    PDF Downloaded67    
    Comments [Add]    

Recommend this journal